Image de couverture de livre

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mattias Mandorfer, Benedikt Simbrunner, Diana Julie Leeming
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
par: Benedikt Simbrunner, et autres
Publié: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
par: Nina Dominik, et autres
Publié: (2024)

Editorial: Carvedilol Remains the First‐Line Treatment of Portal Hypertension After the CALIBRE Trial
par: Thomas Reiberger, et autres
Publié: (2025)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
par: Benedikt Silvester Hofer, et autres
Publié: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
par: Mathias Jachs, et autres
Publié: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
par: Federica Tavaglione, et autres
Publié: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
par: Lukas Burghart, et autres
Publié: (2026)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
par: Jessica D. Lee, et autres
Publié: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
par: Raj Vuppalanchi, et autres
Publié: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
par: David Mehdi Asgher Niazi, et autres
Publié: (2026)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
par: Nina Dominik, et autres
Publié: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
par: Lukas Burghart, et autres
Publié: (2024)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
par: Runqi Wang, et autres
Publié: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
par: Juan Macias, et autres
Publié: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
par: Maral Amangurbanova, et autres
Publié: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
par: Fai Fai Ho, et autres
Publié: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
par: Suprabhat Giri, et autres
Publié: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
par: Bharati Kochar, et autres
Publié: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
par: Jeffrey D McCurdy, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
par: Xiao‐Dong Zhou, et autres
Publié: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
par: Eunice Yewon Lee, et autres
Publié: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
par: Terry Cheuk‐Fung Yip, et autres
Publié: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
par: Sheila L. Noon, et autres
Publié: (2025)

Editorial: Is TIPSS Implantation Effective in Patients With Portal Hypertensive Gastropathy?
par: Marlene Reincke, et autres
Publié: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
par: Lukas Hartl, et autres
Publié: (2024)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
par: Aurelien Amiot, et autres
Publié: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
par: Jessica A. Fitzpatrick, et autres
Publié: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
par: Cristina Rubín de Célix, et autres
Publié: (2025)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
par: Stefano Siboni, et autres
Publié: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
par: José Luis Rueda García, et autres
Publié: (2026)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
par: Simone Chin, et autres
Publié: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
par: Ting Wang, et autres
Publié: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
par: Ryan Yanzhe Lim, et autres
Publié: (2026)

Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression
par: Qun Zhang, et autres
Publié: (2025)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
par: Takao Miwa, et autres
Publié: (2026)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
par: Kaleb Tesfai, et autres
Publié: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
par: Nicolas Richard, et autres
Publié: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
par: Bernardo de Faria Moraes, et autres
Publié: (2026)